AstraZeneca Drug Gets EU Nod
AstraZeneca's camizestrant recommended for EU approval for breast cancer treatment. Potential boost to company's oncology portfolio.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.